HOME › Research Insight › Roche Diagnostics (Switzerland) and Abbott Laboratories (U.S.) are main leading players in In Vitro Diagnostic (IVD) Market
Roche Diagnostics (Switzerland) and Abbott Laboratories (U.S.) are main leading players in In Vitro Diagnostic (IVD) Market
The global in vitro diagnostics market is a fragmented market with the top five companies,Roche Diagnostics, Siemens Healthcare, Johnson & Johnson, Danaher Corporation, and Abbott Laboratories, governing 58.9% of the total market share. Roche is the leader in the professional diagnostics (clinical chemistry and immunochemistry) market. The company has a broad product portfolio including products under various categories, such as professional diagnostics, tissue diagnostics, molecular diagnostics, and diabetes care. Due to its wide range of diabetes care (Accu-Chek series) products, it has also become a leader in the blood glucose monitoring market. The company adopted product development and innovation as the dominant strategy to sustain its leadership position in the global in vitro diagnostic (IVD) market.
Roche Diagnostics (Switzerland) held the leading position in the global IVD market in 2015. Its prominence in this market can be attributed to its diversified product portfolio that includes a wide range of products for in vitro diagnosis. The company strongly invests in R&D activities to improve its existing product portfolio, as it has a strong pipeline of products for the growing IVD market. Moreover, the company has a wide geographic presence across North America, Europe, the Middle East & Africa, and Asia. The company has also focused on a variety of strategies, such as agreement, new product launches, and expansion, to increase its share in the IVD market. For instance, in August 2016, Roche launched Accu-Chek Guide, a next-generation blood glucose monitoring system that provides advanced accuracy while monitoring the blood glucose level.
Abbott Laboratories (U.S.) is another leading company in the global IVD market. The company has maintained its leadership position through its strong presence across the globe, covering major markets such as North America, Europe, and Asia-Pacific. The company has a strong product portfolio and its FDA and CE Mark-approved products have helped it to further enhance its presence in the IVD market. The company has adopted new product launches as its key strategy, followed by agreement and collaboration, to maintain its leading position and increase its market share. For instance, in August 2016, Abbott launched Alinity, a family of next-generation systems for point-of-care testing, immunoassay, clinical chemistry, hematology, blood & plasma screening, and molecular diagnostics.
In the past three years, a majority of the top players have adopted new product launches; acquisition, agreements, collaboration, and partnerships; and geographic expansion as their key growth strategies. New product launches was the preferred strategy adopted by key players in the global IVD market.
In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021
Markets and Markets
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India